Skip to main content
. 2023 Dec 8;11(1):550–559. doi: 10.1002/ehf2.14604

Figure 1.

Figure 1

Overview of proposed sequencing strategies. ACE‐I, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BB, beta‐blocker; BP, blood pressure; CKD, chronic kidney disease; HK, hyperkalaemia; HR, heart rate; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium–glucose co‐transporter 2 inhibitor.